HTG Molecular Announces Executive Transition Plan
Chief Executive Officer TJ Johnson to assume role of Executive Chairman at the end of first quarter 2019
“TJ has been a tremendous leader and a passionate advocate during his 11 years as CEO of the company. His strategic vision and steadfast guidance have put HTG on a path of growth for years to come,” said
TJ Johnson, CEO of HTG added, “It has been a tremendous honor to lead this incredibly talented team, and I couldn’t be more pleased to have John be named as my successor. John is a well-respected executive, who has shown tremendous leadership qualities and has been a trusted “co-pilot” with me over the many years I have known him. HTG is on solid footing, the management team is firmly in place, and I think now is an ideal time for me to step into the Executive Chair role where I can and will continue to focus on strategic growth and business development opportunities for HTG while supporting John and the team. I have full confidence in a seamless transition.”
“TJ has been an incredible mentor over the years and I’m excited to step into the role of CEO. I look forward to continuing to build upon our successes and executing on our strategic plan, while benefitting from TJ’s continued support as Executive Chair,” said
Mr. Lubniewski has served as President and Chief Operating Officer since April 2018. He joined HTG in 2011 as Chief Business Officer and has been instrumental in establishing HTG’s growing customer base and building its key partnerships. Prior to HTG, Mr. Lubniewski served in several leadership roles at Ventana, a medical diagnostics company and member of the
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our newly appointed director and her expected benefits to us and the capabilities of our technology. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of first party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of first parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the
Ashley R. Robinson LifeSci Advisors, LLCPhone: (617) 535-7742 Email: email@example.com TJ Johnson Chief Executive Officer HTG Molecular DiagnosticsEmail: firstname.lastname@example.org
Source: HTG Molecular Diagnostics, Inc.